AstraZeneca PLC AZN StarRatingValueLabel_3Damien Conover, CFA - Sector Director - Morningstar Inc.

Last Price
12,050.00
Day Change
-106.00|-0.87%

As of 03/05/2024
19:09:05 BST | GBX  Minimum 15 Minutes Delay.

Bid/OfferDay RangeVolume90d Ave VolMkt Cap
11,500.00 - 12,200.0012,010.00 - 12,178.001,642,7832,919,228186.80Bil
Last Close52 Week RangeP/EYield %ISIN
12,156.009,461.00 - 12,488.0037.311.89GB0009895292

AstraZeneca Share Price

Morningstar's Take AZN

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The strong replenishment of new drugs is setting up industry-leading growth.

Fair Value Estimate

12,400.00 GBX

Uncertainty

Average

Economic Moat

Wide

Financial Strength

Financial Strength
There is no one analyst in which a Quantitative Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.’s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here.

Total Returns 03/05/2024

 Chg (%)  
AstraZeneca PLC14.09 
FTSE 100 TR GBP3.87
 
Financials
202120222023
more...
Income Statement
Turnover37,417.0044,351.0045,811.00
Operating Profit-139.004,512.008,722.00
Net Profit115.003,293.005,961.00
Reported EPS0.082.113.81
Balance Sheet
Current Assets25,876.0022,443.0025,054.00
Non Current Assets79,119.0073,890.0076,065.00
Total Assets105,363.0096,483.00101,119.00
Current Liabilities22,594.0026,293.0030,542.00
Total Liabilities66,076.0059,425.0061,953.00
Total Equity39,287.0037,058.0039,166.00
Cash Flow
Operating Cash Flow7,706.0011,431.0012,711.00
Net Change in Cash-1,446.0025.00-286.00

Regulatory News

DateAuthor Headline
19/02/2024Jocelyn Jovene Europe's Magnificent 7 Stocks Are Profitable - And Cheaper
Four years ago analysts at Goldman Sachs came up with the GRANOLAS acronym for Europe's leading stocks
24/11/2020Damien Conover Covid Vaccine Breakthrough: the Morningstar View
Morningstar analyst Damien Conover looks in detail at the latest vaccine developments from AstraZeneca and Pfizer/BioNTech
29/10/2019James Gard Brexit Investment Strategies for Uncertain Times
With a General Election slated for December and Brexit postponed until 2020, investors should consider how their portfolios are positioned for more months of uncertainty 
Director Dealings
TradedActionNotifierPriceAmountValue
more...
08/03/2024Transfer inMr. Pascal Soriot0.00105,2380.00
05/03/2024Transfer inMr. Pascal Soriot0.0017,7020.00
20/02/2024Transfer inMr. Pascal Soriot0.0012,3450.00
12/12/2023PurchaseMs. Anna Olive Magdelene Manz10,189.5648749,623.00

Company Profile

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

Sector

Healthcare

Industry

Drug Manufacturers - General

Stock Style

Large-Growth

Fiscal Year Ends

December

Employees

89,900

Next Event 25/07/2024

Half-Yearly Results
Ratios
Comp
PER (E)37.40
Div Yld (E)1.89
PEG (E)0.94
ROCE12.03
Op Mrgn19.00
EPS Grwth0.64
Dividends
PreviousLatest
more...
Record Date11/08/2323/02/24
Ex-Div10/08/2322/02/24
Paid11/09/2325/03/24
Amnt71.80156.00
Directors
more...
Non-Executive DirectorMs. Sherilyn D. McCoy
Non-Executive DirectorDr. Andreas Rummelt
Non-Executive DirectorMr. Marcus Wallenberg
Non-Executive Director, ChairmanMr. Michel Demare
Executive Director, Chief Executive OfficerMr. Pascal Soriot
Non-Executive Director, Senior Independent DirectorMr. Philip A J Broadley
Non-Executive DirectorMs. Diana Layfield
Non-Executive DirectorMs. Deborah DiSanzo
Non-Executive DirectorMs. Anna Olive Magdelene Manz
Non-Executive DirectorProfessor Nazneen Rahman
Executive Director, Chief Financial OfficerDr. Aradhana Sarin
Non-Executive DirectorProfessor Tony Mok
Non-Executive DirectorDr. Euan Ashley
Damien Conover, CFA - Sector Director - Morningstar Inc.
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures